The KOSPI index has surpassed the 3130 mark during trading. This is the highest level in about 3 years and 9 months.
Expectations for the early passage of the Commercial Act amendment have lent a tailwind to the domestic securities market. This shift comes as the People Power Party, which had opposed the amendment, is showing a more progressive stance.
As the United States' reciprocal tariff 90-day deferment approaches its end on the 8th of next month, there are also rising expectations for trade negotiations. Overnight, the New York stock market saw the S&P 500 and Nasdaq indices close at record highs for two consecutive days.
As of 10:12 a.m. on the 1st, the KOSPI index is recording a rise of 55.13 points (1.79%) to reach 3126.83 compared to the previous transaction.
The KOSPI index started at 3089.64, up 17.94 points (0.58%) from the previous session, and increased its gains, reaching 3131.05 early in the session. This is the highest level in about 3 years and 9 months since September 28, 2021 (3134.46).
In the securities market, foreign and institutional investors are net buying 200 billion won and 400 billion won, respectively, boosting the index. Individual investors are selling off 560 billion won worth alone.
Among the top market capitalization stocks in the securities market, Samsung Electronics, Samsung Biologics, and Hyundai Motor are experiencing strong performance. In particular, stocks of holding companies expected to benefit from the Commercial Act amendment, such as Hanwha, HS HYOSUNG, KOLON, and LG, are rising significantly. Meanwhile, SK hynix and Doosan Enerbility are seeing their stock prices decline.
The KOSDAQ index is up 5.17 points (0.66%) at 786.67 compared to the previous day. In the KOSDAQ market, institutions are net buying 31 billion won. Individuals and institutions are showing sell-side dominance at 16 billion won and 13 billion won, respectively.
Among the top market capitalization stocks in the KOSDAQ market, the stock prices of Alteogen, ECOPRO BM, HLB, and Peptron are rising. In contrast, PharmaResearch, LigaChem Biosciences, and CLASSYS are seeing declines in their stock prices.